Plain-English translation of NCT05197270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called 4D-150, which is a gene therapy delivered as a single injection into the eye. It's designed for people with wet age-related macular degeneration (a condition causing vision loss in older adults) who are already responding well to current eye injections. Researchers want to see if this medication can provide longer-lasting benefit and potentially reduce the need for frequent future injections.
Current treatments for wet macular degeneration require repeated eye injections every month or every few months, which is burdensome for patients. This trial exists to test whether a single-dose gene therapy treatment could provide lasting improvement and reduce the frequency of future injections needed.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive one injection of the new medication into your eye on Day 1. You will then return to the clinic monthly for the first 2 years for eye exams and imaging tests to check your vision and eye health. After that, you will continue follow-up visits yearly for an additional 3 years. The entire study commitment is 5 years. Some participants may also be eligible to receive the treatment in their second eye if their first eye responds well, or to participate in additional research measuring how the treatment breaks down in the body.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States